Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network

  Advanced Search  

Editorial Manager(tm) for PLoS Pathogens Manuscript Draft

Summary: Editorial Manager(tm) for PLoS Pathogens
Manuscript Draft
Manuscript Number:
Title: Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin
Impedes the Selection of Drug-Resistant Influenza A Virus
Short Title: TCAD impedes drug resistance in influenza in vitro
Article Type: Research Article
Section/Category: Virology
Keywords: influenza; antiviral; resistance; combination therapy; amantadine; oseltamivir; ribavirin
Corresponding Author: Jack T. Nguyen
Corresponding Author's Institution: Adamas Pharmaceuticals, Inc.
First Author: Justin D. Hoopes
Order of Authors: Justin D. Hoopes;Elizabeth M. Driebe;Erin Kelley;David M. Engelthaler;Paul S.
Keim;Alan S. Perelson;Libin Rong;Matthew Gross;Amy K. Patick;Gregory T. Went;Jack T. Nguyen
Abstract: The widespread resistance among circulating influenza A strains to at least one of the anti-
influenza drugs is a major public health concern. A triple combination antiviral drug (TCAD) regimen
comprised of amantadine, oseltamivir, and ribavirin has been shown to have synergistic and broad
spectrum activity against influenza A strains, including drug resistant strains. Here, we used
mathematical modeling along with three different experimental approaches to determine the effects of
single agents, double combinations, and the TCAD regimen on resistance in influenza in vitro, including:


Source: Ahlers, Guenter - Department of Physics, University of California at Santa Barbara


Collections: Physics